Evaluate the renal system damage caused by zoledronic acid: a comprehensive analysis of adverse events from FAERS

Evaluate the renal system damage caused by zoledronic acid: a comprehensive analysis of adverse events from FAERS

Abstract Background Zoledronic acid (ZA) is widely used for the treatment of osteolytic bone metastases in malignancies and osteoporosis, but it has been associated with renal impairment. In this study, we investigated adverse events (AEs) related to renal and urinary system diseases associated with...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhaojun Wang, Xin Su, Donglei Shi, Li Wei
Format:	Article
Language:	English
Published:	BMC 2024-12-01
Series:	BMC Cancer
Subjects:	Zoledronic acid FDA adverse event reporting system Adverse events
Online Access:	https://doi.org/10.1186/s12885-024-13284-5
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Adverse events in different administration routes of amiodarone: a pharmacovigilance study based on the FDA adverse event reporting system
by: Jingrong Yang, et al.
Published: (2025-01-01)

A real−world pharmacovigilance study of FDA Adverse Event Reporting System events for pralsetinib
by: Yi Yin, et al.
Published: (2024-11-01)

Drug-induced retinal vein occlusion: a disproportionality analysis from the FDA adverse event reporting system (2004–2023)
by: Xiao-Dong Chen, et al.
Published: (2024-12-01)

Adverse events in the nervous system associated with blinatumomab: a real-world study
by: Wen Gao, et al.
Published: (2025-02-01)

Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS) database
by: Wen-Hui Liu, et al.
Published: (2024-11-01)

Cardiovascular toxicity of tisagenlecleucel in children and adolescents: analysis of spontaneous reports submitted to FAERS
by: Ganggang Wang, et al.
Published: (2025-01-01)

Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS)
by: Hui Gao, et al.
Published: (2025-01-01)

Precision Adverse Drug Reactions Prediction with Heterogeneous Graph Neural Network
by: Yang Gao, et al.
Published: (2025-01-01)

Mogamulizumab‐Associated Autoimmune Diseases: Insights From FAERS Database Analysis
by: Genshan Zhang, et al.
Published: (2024-12-01)

Progressive multifocal leukoencephalopathy reports in rheumatoid arthritis concerning different treatment patterns-an exploratory assessment using the food and drug administration adverse event reporting system
by: Takeshi Honma, et al.
Published: (2024-05-01)

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system
by: Ruichen Gao, et al.
Published: (2025-02-01)

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01)

Adverse event profiles of selpercatinib: a real-world pharmacovigilance analysis based on FAERS database
by: Jiancheng Qian, et al.
Published: (2024-12-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for avatrombopag
by: Zhong Xue, et al.
Published: (2024-11-01)

Ophthalmic corticosteroids-related adverse events: the FDA adverse event reporting system (FAERS) database pharmacovigilance study
by: Chengzhi Liu, et al.
Published: (2024-12-01)

Safety assessment of deutetrabenazine: real-world adverse event analysis from the FAERS database
by: Yanping Shu, et al.
Published: (2024-12-01)

Signal detection and analysis of adverse events associated with Genvoya® based the FAERS database
by: Chengliang Wang, et al.
Published: (2024-12-01)

Data mining and analysis of adverse events of Vedolizumab based on the FAERS database
by: Qinyun Xu, et al.
Published: (2025-01-01)

Unveiling the Hidden Risks: An Update Decade-Long Analysis of Abraxane-Related Adverse Events from the FAERS Database
by: Zhao YC, et al.
Published: (2024-11-01)

Fatal outcome related to drug reaction with eosinophilia and systemic symptoms: a disproportionality analysis of FAERS database and a systematic review of cases
by: Chunsu Liang, et al.
Published: (2024-12-01)

Association of incretin-based therapies with hepatobiliary disorders among patients with type 2 diabetes: a case series from the FDA adverse event reporting system
by: Yankun Liang, et al.
Published: (2024-11-01)

Analysis of the risk of oncological adverse events associated with infliximab in combination with azathioprine compared to monotherapy: insights from the FAERS database
by: Qian Qiao, et al.
Published: (2025-01-01)

Safety assessment of disulfiram: real-world adverse event analysis based on FAERS database
by: Jing Luo, et al.
Published: (2024-11-01)

A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases
by: Qian Liu, et al.
Published: (2024-11-01)

Comprehensive analysis of adverse events associated with onasemnogene abeparvovec (Zolgensma) in spinal muscular atrophy patients: insights from FAERS database
by: Wenwen Zhang, et al.
Published: (2025-01-01)

Safety assessment of tolvaptan: real-world adverse event analysis using the FAERS database
by: Peiyang Cao, et al.
Published: (2025-01-01)

Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: case report and thematic analysis of one participant's experience
by: Mourad Wahba, et al.
Published: (2024-11-01)

High-risk adverse events in two types of single inhaler triple-therapy: a pharmacovigilance study based on the FAERS database
by: Zhishen Ruan, et al.
Published: (2025-01-01)

The effect of denosumab vs. zoledronic acid in preventing skeletal-related events, including pain-related bone metastasis: a systematic review
by: I. Putu Eka Widyadharma, et al.
Published: (2024-10-01)

PSA LEVEL AND ADVERSE EVENTS IN SIXTH AND TENTH SERIES DOCETAXEL CHEMOTHERAPY IN CASTRATE-RESISTANT PROSTATE CANCER (CRPC) PATIENTS
by: Kurnia Penta Seputra, et al.
Published: (2025-01-01)

Analyzing the adverse events of NK-1 receptor antagonists: a pharmacovigilance study from the FAERS database
by: Hong Pan, et al.
Published: (2024-12-01)

Pharmacovigilance study of famciclovir in the Food and Drug administration adverse event reporting system database
by: Runan Fang, et al.
Published: (2024-11-01)

Adverse event profile of lorazepam: a real-world pharmacovigilance study using the FDA adverse event reporting system database
by: Zhengkang Su, et al.
Published: (2024-11-01)

Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database
by: Yamin Shu, et al.
Published: (2023-02-01)

Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations
by: Benjamin C. Park, et al.
Published: (2023-12-01)

A decade-long overview of adverse events in a tertiary surgical service in South Africa
by: H Wain, et al.
Published: (2024-10-01)

Drug-induced Parkinson-like events: a real-world study from 2004 to the first quarter of 2024 based on FAERS
by: Ke Wang, et al.
Published: (2025-01-01)

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
by: Shiyi Wang, et al.
Published: (2025-02-01)

Safety profiles of sevoflurane in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database
by: Chuang Yang, et al.
Published: (2025-02-01)

Faecal microbiota transplantation associated adverse events
by: Patryn Rafal, et al.
Published: (2024-09-01)